Novartis Pharma S.A.S.

Research activity is centred on chronic myeloid leukaemia, with particular attention to CML-CP and CML-AP in patients carrying the T315I mutation.

• Chronic myeloid leukaemia
• CML-CP and CML-AP
• T315I mutation

The therapeutic focus includes patients with resistance, intolerance, or ineligibility to prior tyrosine kinase inhibitor options.